Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
OCRELIZUMAB 300MG/10ML 24852 (CDM 781024852) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved October 21, 2026 , from http://ppman.hank.ai/transparency/procedure/781024852/by-state?code_type=CDM
“OCRELIZUMAB 300MG/10ML 24852 (CDM 781024852) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/781024852/by-state?code_type=CDM. Accessed
October 21, 2026 .
“OCRELIZUMAB 300MG/10ML 24852 (CDM 781024852) by State,” HANK Price Transparency ,
accessed October 21, 2026 ,
http://ppman.hank.ai/transparency/procedure/781024852/by-state?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
CDM · across United States
781024852 — Ocrelizumab 300mg/10ml 24852
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$24,154
National median
$23,080 – $42,940
IQR (p25 – p75)
6
hospitals filing
1
states
Walking in without insurance?
Cash / self-pay price
Cash median
$19,860
vs. negotiated
-17.8%
Hospitals reporting
6
Cash / self-pay rates apply when you don't run the bill through insurance.
Many hospitals also offer income-based discounts on top of the published
cash price — always ask about a financial-assistance application
before paying.
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 781024852 (CDM), with interquartile range
State Median p25 p75
OK $24,154 $23,080 $42,940